Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Invested Capital (2016 - 2025)

Historic Invested Capital for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $22.0 million.

  • Lineage Cell Therapeutics' Invested Capital fell 6598.45% to $22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.0 million, marking a year-over-year decrease of 6598.45%. This contributed to the annual value of $78.4 million for FY2024, which is 2359.23% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Invested Capital of $22.0 million as of Q3 2025, which was down 6598.45% from $48.4 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Invested Capital high stood at $124.7 million for Q2 2021, and its period low was $22.0 million during Q3 2025.
  • In the last 5 years, Lineage Cell Therapeutics' Invested Capital had a median value of $73.5 million in 2022 and averaged $77.7 million.
  • Its Invested Capital has fluctuated over the past 5 years, first surged by 3223.2% in 2021, then plummeted by 6598.45% in 2025.
  • Lineage Cell Therapeutics' Invested Capital (Quarter) stood at $92.3 million in 2021, then decreased by 20.38% to $73.5 million in 2022, then decreased by 13.66% to $63.4 million in 2023, then rose by 23.59% to $78.4 million in 2024, then crashed by 71.88% to $22.0 million in 2025.
  • Its Invested Capital stands at $22.0 million for Q3 2025, versus $48.4 million for Q2 2025 and $79.0 million for Q1 2025.